KR100992042B1 - preparation for cosmetic composition containg ginseng extract stabilized by nanoliposome - Google Patents
preparation for cosmetic composition containg ginseng extract stabilized by nanoliposome Download PDFInfo
- Publication number
- KR100992042B1 KR100992042B1 KR1020080035200A KR20080035200A KR100992042B1 KR 100992042 B1 KR100992042 B1 KR 100992042B1 KR 1020080035200 A KR1020080035200 A KR 1020080035200A KR 20080035200 A KR20080035200 A KR 20080035200A KR 100992042 B1 KR100992042 B1 KR 100992042B1
- Authority
- KR
- South Korea
- Prior art keywords
- wild ginseng
- ginseng extract
- nanoliposomes
- effect
- cosmetic composition
- Prior art date
Links
- 235000020710 ginseng extract Nutrition 0.000 title claims abstract description 56
- 239000002537 cosmetic Substances 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title description 4
- 241000208340 Araliaceae Species 0.000 claims abstract description 25
- 235000008434 ginseng Nutrition 0.000 claims abstract description 25
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 24
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 24
- 230000002087 whitening effect Effects 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 15
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002502 liposome Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 108010024636 Glutathione Proteins 0.000 claims description 5
- 229960003180 glutathione Drugs 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 229940068977 polysorbate 20 Drugs 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 54
- 102000003425 Tyrosinase Human genes 0.000 abstract description 29
- 108060008724 Tyrosinase Proteins 0.000 abstract description 29
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 28
- 230000002401 inhibitory effect Effects 0.000 abstract description 28
- 230000008099 melanin synthesis Effects 0.000 abstract description 16
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 abstract description 14
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 abstract description 14
- 238000002845 discoloration Methods 0.000 abstract description 14
- 239000000126 substance Substances 0.000 abstract description 14
- 230000037303 wrinkles Effects 0.000 abstract description 14
- 238000001556 precipitation Methods 0.000 abstract description 12
- 238000000926 separation method Methods 0.000 abstract description 11
- 102000029816 Collagenase Human genes 0.000 abstract description 7
- 108060005980 Collagenase Proteins 0.000 abstract description 7
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 7
- 229960002424 collagenase Drugs 0.000 abstract description 7
- 208000003351 Melanosis Diseases 0.000 abstract description 5
- 206010014970 Ephelides Diseases 0.000 abstract description 4
- 239000003963 antioxidant agent Substances 0.000 abstract description 4
- 230000001629 suppression Effects 0.000 abstract description 4
- 230000001153 anti-wrinkle effect Effects 0.000 abstract description 2
- 230000007760 free radical scavenging Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 17
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 14
- 108010035532 Collagen Proteins 0.000 description 14
- 229920001436 collagen Polymers 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 230000032683 aging Effects 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 12
- 210000002752 melanocyte Anatomy 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 229960000271 arbutin Drugs 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 8
- 229930182490 saponin Natural products 0.000 description 8
- 150000007949 saponins Chemical class 0.000 description 8
- 235000017709 saponins Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 235000003228 Lactuca sativa Nutrition 0.000 description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 5
- 229930182494 ginsenoside Natural products 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229960004441 tyrosine Drugs 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 102000013382 Gelatinases Human genes 0.000 description 4
- 108010026132 Gelatinases Proteins 0.000 description 4
- 241000208822 Lactuca Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940089161 ginsenoside Drugs 0.000 description 4
- 229940069445 licorice extract Drugs 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 240000008415 Lactuca sativa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002780 melanosome Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- -1 chlorine ions Chemical class 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 239000008271 cosmetic emulsion Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000020688 green tea extract Nutrition 0.000 description 2
- 229940094952 green tea extract Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000037331 wrinkle reduction Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229940075894 denatured ethanol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000006903 response to temperature Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 초고압처리기를 사용하여 압력 1000MPa, 온도 70℃에서 30분간 처리하여 산삼을 추출하는 단계; 상기 추출한 산삼 추출물을 나노리포좀으로 안정화시키는 단계를 포함하는 것을 특징으로 하는 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 제조방법에 관한 것으로, 기미, 주근깨 및 피부 색소 침착의 원인이 되는 물질인 멜라닌 생성을 막아주는 티로시나제 활성 억제효과, 멜라닌 합성 억제효과 등의 미백효과와 자유라디칼 소거 효과, 콜라게나제(MMP-1)의 활성 및 발현억제 등의 주름개선효과가 우수하고, 온도 변화에 대해 변색과 분리 및 침전이 발생하지 않는 우수한 안정성을 갖는다. The present invention comprises the steps of extracting wild ginseng by processing for 30 minutes at a pressure of 1000MPa, temperature 70 ℃ using an ultra high pressure processor; The present invention relates to a method for preparing a cosmetic composition containing a ginseng extract stabilized with nanoliposomes, comprising stabilizing the extracted ginseng extract with nanoliposomes, which are substances causing blemishes, freckles, and skin pigmentation. Excellent anti-wrinkle effect such as whitening effect such as tyrosinase activity inhibiting melanin prevention, melanin synthesis inhibitory effect, free radical scavenging effect, collagenase (MMP-1) activity and expression suppression It has excellent stability without discoloration and separation and precipitation.
나노리포좀, 멜라닌, 산삼, 주름, 항산화, 화장료 Nanoliposomes, melanin, wild ginseng, wrinkles, antioxidants, cosmetics
Description
본 발명은 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 제조방법에 관한 것으로 더욱 상세하게는 산삼추출물에 나노리포좀을 함유시켜 안정화된 산삼 추출물을 함유하는 화장료 조성물의 제조방법에 관한 것이다.The present invention relates to a method for preparing a cosmetic composition containing a wild ginseng extract stabilized with nanoliposomes, and more particularly, to a method for preparing a cosmetic composition containing a stabilized wild ginseng extract by containing nanoliposomes in a wild ginseng extract.
피부색을 결정하는 인자는 기본적으로 인종과 지역, 성별, 나이에 따른 차이를 배제하면 기미, 주근깨와 자외선 노출로 인한 태닝과 같은 부분적 또는 전체적인 색소침착과 여드름 및 흉터, 각질의 분포 상태와 혈액 순환, 스트레스, 건강상태 등이 있다.The factors that determine skin color are basically partial or total pigmentation such as blemishes, freckles and tanning due to freckle and UV exposure, and the distribution of acne and scars, keratin distribution, blood circulation, Stress, health status.
이상의 인자들 가운데에서도 피부색을 결정하는 가장 중요한 인자는 색소침착이다. 피부색에 영향을 주는 색소로는 멜라닌, 카로틴, 헤모글로빈 등이 있는데 이중 가장 중요한 것은 멜라닌으로 이러한 멜라닌 생합성에 영향을 미치는 가장 큰 요인은 자외선과 체내 호르몬 분비 정도이다. 멜라닌의 생합성은 아미노산의 일종 인 티로신이 멜라노사이트의 멜라노좀에서 티로시나제(tyrosinase)에 의해 산화되어 디하이드록시 페닐알라닌(dihydroxyphenylalanine)으로 전환되는 것을 시작으로 계속되는 일련의 산화과정을 거쳐 갈색(pheomelanin), 흑색(eumelanin)의 중합체로 형성된다. 이러한 생합성 과정은 멜라노좀이라는 특수한 형태의 갈색 세포내 소기관에서 진행되며 멜라닌 과립을 포함한 멜라노좀은 핵 주변 부위에서 수지상 돌기 끝부분으로 이동, 케라티노사이트의 식세포작용에 의해 세포질 내로 이동하고 이들은 케라티노사이트의 핵 주변에 축적된다. 멜라닌의 합성과 멜라노좀의 수, 주위의 케라티노사이트로의 이동은 부분적으로 호르몬과 자외선 등에 영향을 받고 일차적으로는 유전적인 영향을 크게 받는다.Among the above factors, the most important factor for determining skin color is pigmentation. The pigments that affect skin color include melanin, carotene, and hemoglobin, the most important of which is melanin. The most important factors affecting melanin biosynthesis are ultraviolet rays and hormones in the body. The biosynthesis of melanin is brown and black through a series of oxidation processes, beginning with the conversion of tyrosine, an amino acid, from the melanoma of melanocytes to tyrosinase and dihydroxyphenylalanine. (eumelanin) polymer. This biosynthesis process is carried out in a special type of brown intracellular organelles called melanosomes. Melanosomes, including melanin granules, move from the periphery of the nucleus to the dendritic end, and then into the cytoplasm by the phagocytosis of keratinocytes. Accumulate around the nucleus of the site. The synthesis of melanin, the number of melanosomes, and the movement to surrounding keratinocytes are partially affected by hormones and ultraviolet rays, and primarily by genetic influences.
그 밖에 티로시나제의 발현 및 멜라닌의 합성, 전송에 관여하는 세포내 조절인자인 싸이토카인(cytokine), 구리, 아연, 철 등의 금속 이온 및 인터페론, 프로스타글란딘, 히스타민 등이 관여하는 것으로 알려져 있다(박수남, 대한화장품학회지, 25: 77-127, 1999). 따라서 피부색을 결정짓는 멜라닌의 합성을 억제하고 이에 관여하는 효소인 티로시나제의 활성을 억제하여 피부의 미백효과를 기대할 수 있다.In addition, intracellular regulators such as cytokines, copper, zinc and iron, interferon, prostaglandin and histamine, which are involved in the expression of tyrosinase, synthesis and transfer of melanin, are known to be involved. Society of Cosmetic Scientists, 25: 77-127, 1999). Therefore, the skin whitening effect can be expected by inhibiting the synthesis of melanin, which determines the skin color, and the activity of tyrosinase, an enzyme involved therein.
종래에는, 기미, 주근깨, 색소침착 등과 같은 피부색소 이상침착 증상과 자외선 노출 등에 의해 발생한 과도한 멜라닌 색소침착을 치료 또는 경감시켜주기 위해서, 이전부터 아스코르빈산, 코지산, 알부틴, 하이드로퀴논, 글루타치온 또는 이들의 유도체, 티로시나제 저해활성을 가진 물질들을 화장료나 의약품에 배합 사용하여 왔다.Conventionally, ascorbic acid, kojic acid, arbutin, hydroquinone, glutathione, or the like in order to treat or alleviate excessive melanin pigmentation caused by abnormal symptoms of skin pigmentation such as blemishes, freckles, pigmentation, and UV exposure. These derivatives and substances having tyrosinase inhibitory activity have been used in cosmetics and pharmaceuticals.
그러나 이들은 매우 불안정하고, 피부로의 전달이 용이하지 않아 특별한 안정화 시스템과 전달 체계가 필요하며, 불충분한 미백효과, 피부에 대한 안전성 문제, 화장료에 배합시 제형 및 안정성 문제 등으로 인해 그 사용이 제한되고 있다.However, they are very unstable and difficult to deliver to the skin, requiring a special stabilization system and delivery system, and their use is limited due to insufficient whitening effects, safety issues with the skin, formulation and stability problems when formulated in cosmetics, etc. It is becoming.
한편, 현재 이들 기존 미백 효능 물질들 이외에 천연물 중에서 미백 활성성분을 찾기 위한 연구가 계속 이루어지고 있는데, 그 중 상백피 (일본공개특허 소(昭)55-44375, 소(昭)64-26507, 소(昭)64-83009, 평(平)1-25687, 평(平)5-139950, 한국공개특허 제1992-002109호, 제1997-021273호), 감초(일본공개특허 소(昭)60-214721, 소(昭)63-23809, 소(昭)64-63506, 평(平)1-149706, 한국공개특허 제1992-002109호, 제1997-025601호) 등 다수의 식물추출물이 티로시나제에 작용하여 멜라닌 생성을 억제한다는 사실이 밝혀졌으나, 이들 역시 안전성, 안정성, 변색 가능성 등의 측면에서 화장품이나 의약품에 유효 농도 이상으로 사용하는 데는 많은 문제점이 있으며 만족 할 만한 효과를 내지 못하는 실정이다.Meanwhile, in addition to these existing whitening efficacy substances, research is being conducted to find whitening active ingredients among natural products. Among them, baekbaekpi (Japanese Patent Application No. 55-44375, cow 64-26507, cow ( -) 64-83009, 1-1-25687, 5-5-139950, Korean Laid-Open Patent Nos. 1992-002109, 1997-021273), Licorice (Japanese Laid-Open Patent Publication 60-214721) , Bovine 63-23809, bovine 64-63506, pyeong 1-49706, Korean Laid-Open Patent No. 1992-002109, 1997-025601) and many other plant extracts act on tyrosinase. Although it has been found that it inhibits melanin production, they also have many problems in use above the effective concentration in cosmetics or pharmaceuticals in terms of safety, stability, discoloration, etc. and do not produce satisfactory effects.
다음으로, 피부에 영향을 미치는 인자로는 피부의 노화로 인한 주름의 생성과 탄력의 저하이다. 사람의 피부는 나이를 먹으면서 피부노화와 색소침착에 의해 끊임없이 변한다. 피부노화는 크게 자연 노화(혹은 내인성 노화)와 외적 노화로 구분되며(EB Doris, Cosmetics & Toiletories, 111: 31-37, 1996), 자연 노화는 유전적인 요소에 영향을 받기 때문에 인위적인 조절이 어려운 반면 외적 노화는 환경적인 요소에 영향을 받기 때문에 인위적인 조절이 비교적 용이하다. 대표적인 외적 노화 인자로는 자외선을 들 수 있으며, 가장 두드러진 외적인 노화 현상이 바로 주름 형성이다(HW Daniel, Ann Intern Med, 75(6): 873-880, 1971; GL Grove, et al., J Am Acad Dermatol, 21: 631-637, 1989; CE Griffiths, et al., Arch Dermatol, 128: 347-351, 1992).Next, factors affecting the skin include the generation of wrinkles and the decrease in elasticity due to aging of the skin. Human skin is constantly changing with age and skin aging. Skin aging is largely divided into natural aging (or endogenous aging) and external aging (EB Doris, Cosmetics & Toiletories, 111: 31-37, 1996). While natural aging is influenced by genetic factors, it is difficult to control artificially. External aging is relatively easy due to environmental factors. Representative external aging factors include ultraviolet rays, and the most prominent external aging phenomenon is wrinkle formation (HW Daniel, Ann Intern Med, 75 (6): 873-880, 1971; GL Grove, et al., J Am) Acad Dermatol, 21: 631-637, 1989; CE Griffiths, et al., Arch Dermatol, 128: 347-351, 1992).
자외선에 의해 야기되는 광노화 메카니즘 중의 하나는 자유 라디칼 경로를 경유하는 것이다(D Harman, J Gerontol, 11(3): 298-301, 1956). 자유 라디칼들은 피부 콜라겐 등의 결합조직형성 파괴, 세포막 기능저해, DNA 변이촉진, 단백질 작용 변형, 세포간 에너지 전이, 신진대사와 관련된 분자들의 변형 등을 유발하는 것으로 알려져 있다(AF Kligman and RM Lavker, J Cutan Aging Cosmet Dermatol, 1: 5-12, 1988). 노화에 자유 라디칼이 관여한다는 사실은 자유 라디칼을 불활성화하는 항산화제 또는 여러 가지 화학적 소거제들을 사용하여 노화 과정을 지연시킬 수 있다는 것을 의미한다.One of the photoaging mechanisms caused by ultraviolet light is via free radical pathways (D Harman, J Gerontol, 11 (3): 298-301, 1956). Free radicals are known to cause breakdown of connective tissue formation, such as cutaneous collagen, cell membrane dysfunction, DNA mutation, protein action, intercellular energy transfer, and metabolism-related molecules (AF Kligman and RM Lavker, J Cutan Aging Cosmet Dermatol, 1: 5-12, 1988). The fact that free radicals are involved in aging means that antioxidants or various chemical scavengers that inactivate the free radicals can be used to delay the aging process.
생체 내에서 콜라겐과 같은 세포외 기질의 합성과 분해는 적절하게 조절되나 노화가 진행되면서 그 합성이 감소하며 콜라겐을 분해하는 효소인 기질 금속단백질 분해효소(matrixmetalloproteinase, 이하 'MMP'라 칭함), 특히 콜라게나제(collagenase, 이하 'MMP-1'이라 칭함)와 젤라티나제 (gelatinase, 이하 'MMP-2'라 칭함)의 발현이 촉진되어 피부의 탄력이 저하되고 주름이 형성된다. 또한 자외선 조사와 자유 라디칼에 의해 이러한 분해효소가 활성화되기도 한다.In vivo, the synthesis and degradation of extracellular matrix such as collagen is properly regulated, but its synthesis decreases with aging and matrix metalloproteinase (MMP), an enzyme that breaks down collagen, especially Expression of collagenase (hereinafter referred to as 'MMP-1') and gelatinase (gelatinase (hereinafter referred to as 'MMP-2')) is promoted, thereby reducing the elasticity of the skin and forming wrinkles. Ultraviolet radiation and free radicals also activate these degrading enzymes.
MMP는 그 기질특이성에 따라 MMP-1, MMP-2, MMP-9로 크게 분류되는데, MMP-1은 간질의 효소인 섬유아세포 타입 콜라게나제이며 기질로는 콜라겐 타입 Ⅰ,Ⅱ,Ⅲ,Ⅶ,Ⅷ,Ⅹ 및 젤라틴이 있으며 원래 콜라겐 길이의 3/4이나 1/4 길이의 펩타이드로 잘라 비특이적인 효소(gelatinase)의 작용이 용이하도록 한다. MMP-2는 72 KD의 젤라티네이즈(A)가 속하며 젤라틴, 콜라겐 타입 Ⅳ,Ⅴ,Ⅶ,Ⅹ, 엘라스틴 및 파이브로넥틴과 같은 기질을 분해한다. 호중구 및 다형핵성 백혈구의 MMP는 산화과정에 의하여 일차적으로 활성화되는데 그 과정은 먼저 세포 내에서 과산화수소가 발생되면 염소 이온의 존재 하에서 미엘로페록시다제(myeloperoxidase)에 의하여 차아염소산으로 전환되고 이것이 MMP를 활성화한다.MMP is classified into MMP-1, MMP-2, and MMP-9 according to its substrate specificity. MMP-1 is a fibroblast type collagenase, an enzyme of epilepsy, and collagen type I, II, III, and 기질 as substrates. There are, Ⅷ, Ⅹ and gelatin, cut into 3/4 or 1/4 length of the original collagen length peptide to facilitate the action of non-specific enzyme (gelatinase). MMP-2 belongs to 72 KD of gelatinase (A) and degrades substrates such as gelatin, collagen types IV, V, VIII, VIII, elastin and fibronectin. MMPs of neutrophils and polymorphonuclear leukocytes are primarily activated by oxidation, which first generates hydrogen peroxide in the cell and is converted to hypochlorous acid by myeloperoxidase in the presence of chlorine ions. Activate it.
자외선에 의한 노화를 방지하기 위하여 자외선 차단제가 함유된 제품을 피부에 직접 도포하는 방법이 가장 일반화되어 있으나, 1988년 레티노인산이 노화된 피부의 피부 거칠음 및 잔주름의 완화에 효과가 있다고 보고 되었고(KS Weiss, et al., JAMA, 259: 527-532, 1988), 전 세계적으로 피부노화를 억제 혹은 개선하는 물질을 개발하기 위한 연구가 활발히 진행되고 있다. 이 중 비타민 A, C, E, 비타민류의 유도체 및 AHA(alpha-hydroxy acid)는 현재까지 알려진 피부노화 개선의 대표적인 물질이다(Hermitte, Cosmetics & Toiletries, 107: 63-67, 1992; DR Rosenthal, et al., J Invest Dermatol, 95: 510-515, 1990; TD Ditre, et al., J Invest Dermatol, 34: 187-195, 1996). 하지만, 이들은 자연환경에서 매우 불안정하여 사용상 문제점이 있거나, 혹은 가시적 효과를 나타내기엔 다소 미흡하다는데 문제가 있다.In order to prevent aging due to ultraviolet rays, the most common method is to apply a product containing sunscreen directly to the skin.However, in 1988, retinoic acid was reported to be effective in reducing skin roughness and fine wrinkles of aged skin (KS Weiss). , et al., JAMA, 259: 527-532, 1988), research is being actively conducted to develop substances that suppress or improve skin aging worldwide. Among them, vitamins A, C, E, derivatives of vitamins and AHA (alpha-hydroxy acid) are representative substances for improving skin aging known to date (Hermitte, Cosmetics & Toiletries, 107: 63-67, 1992; DR Rosenthal, et al., J Invest Dermatol, 95: 510-515, 1990; TD Ditre, et al., J Invest Dermatol, 34: 187-195, 1996). However, they are very unstable in the natural environment, so there is a problem in use, or somewhat insufficient to show a visible effect.
따라서 본 발명자는 천연물에서 피부 미백 및 피부노화 억제에 관한 물질을 찾고자 노력하였고, 산삼에 주목하게 되었다. Therefore, the present inventors have tried to find a substance related to skin whitening and skin aging inhibition in natural products, and came to pay attention to wild ginseng.
인삼(Panax ginseng)은 오갈피나무과( Araliaceae)에 속하는 다년생 초본류로서, 한방에서는 그 뿌리를 인삼(Ginseng Radix)이라 하며 강장(强壯), 강정(强 精), 조혈(造血), 보온(保溫), 건위(健胃), 피로회복, 정신안정, 진정작용 등의 효능이 있는 것으로 알려져 있다. 이러한 인삼의 주요 유효성분으로는 사포닌, 사포게닌, 폴리아세틸렌, 피라진 유도체, 말톨 등이 있으며, 인삼 사포닌은 화학구조의 특성에 따라 프로토파낙사디올(protopanaxadiol)계, 프로토파낙사트리올 (protopanaxatriol)계 및 올레아노난(oleanonane)계 사포닌으로 구분하는데, 현재까지 각각 19종, 10종, 1종의 화합물이 분리 정제되었으며, 디올계와 트리올계는 체내에서의 약리작용이 서로 다른 것으로 알려져 있다. 인삼 사포닌은 다른 식물의 사포닌과 달리 독성이 없고 0.001% 이하에서는 용혈작용을 나타내지 않는 것으로 알려져 있으며, 중추신경 억제작용, 단백질합성 촉진작용, 부신피질호르몬 분비촉진작용, 면역증강작용 등이 있는 것으로 보고되고 있다. 한편, 산삼은 산에 자연적으로 나는 인삼으로, 적응증이나 효용은 인삼과 비슷하나 그 약효가 월등히 뛰어나며, 대표적인 효능으로는 신체 조절 기능의 항상성 유지 작용이라 할 수 있다. 이러한 작용에 근거하여 항피로 및 항스트레스 작용, 혈압조절 작용, 항암작용, 동맥경화 및 고혈압의 예방, 위장기능 강화, 면역기능 강화, 항바이러스 작용 등이 보고되고 있다.Ginseng (Panax ginseng) is a perennial herb belonging to the Araliaceae family, and its root is called Ginseng Radix in oriental medicine, and the tonic, Gangjeong, hematopoietic, warmth, Health, health, fatigue, mental stability, sedative effects are known to be effective. The main active ingredients of ginseng include saponins, sapongenins, polyacetylenes, pyrazine derivatives, maltol, and the like, and ginseng saponins are based on the chemical structure of protopanaxadiol and protopanaxatriol. It is divided into system and oleanonane-based saponins. To date, 19, 10 and 1 compounds have been separated and purified, and diol and triol are known to have different pharmacological effects in the body. Ginseng saponins, unlike other plant saponins, are not toxic and do not show hemolytic action below 0.001%. They are reported to have central nervous system suppression, protein synthesis promotion, adrenal cortex hormone secretion, and immune boosting. It is becoming. On the other hand, wild ginseng is a ginseng naturally occurring in the mountains, indications and utilities are similar to ginseng, but its medicinal effects are excellent, and representative effects can be said to maintain homeostasis of body control functions. Anti-fatigue and antistress action, blood pressure control action, anticancer action, arteriosclerosis and hypertension prevention, gastrointestinal function enhancement, immune function enhancement, antiviral action and the like have been reported based on this action.
한편, 이제까지 화장품의 소재로서 사용된 원료들은 단순히 효소 활성만을 억제하는 것이 대부분이었으며 효소의 발현양은 조절하지 못하는 문제점이 있었다. 또한 최근 소비자들은 점차 특수한 조성에 따른 고품질의 기능적 특성을 가짐과 동시에 피부보호, 자극억제, 염증억제, 일광차단 등의 최소한의 부작용을 갖는 화장품의 사용을 요구하고 있고, 피부자극을 최소화하기 위해 종래의 화학물질 원료를 사용하는 대신에 천연재료를 이용한 화장품에 대한 소비자의 호응이 높아짐에 따라 천연재료를 화장품의 원료로써 개발할 필요성이 한층 제기되고 있다.On the other hand, the raw materials used up to now as a material of cosmetics was mostly to simply inhibit the enzyme activity, there was a problem that can not control the amount of expression of the enzyme. In addition, consumers are increasingly demanding the use of cosmetics with minimal functional side effects such as skin protection, irritation suppression, inflammation suppression, and sun protection while having high quality functional properties according to special composition, and to minimize skin irritation As consumers' response to cosmetics using natural materials instead of using chemical raw materials is increasing, there is a need to develop natural materials as raw materials for cosmetics.
이에 본 발명은 미백효과, 항산화 효과, 잔주름 방지효과, 콜라겔 합성효과를 나타내는 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 제조방법을 제공하는데 그 목적이 있다. Accordingly, an object of the present invention is to provide a method for preparing a cosmetic composition containing a wild ginseng extract stabilized with nanoliposomes exhibiting a whitening effect, antioxidant effect, anti-wrinkle effect, and collagen synthesis effect.
상기 목적을 달성하기 위하여 본 발명은 초고압처리기를 사용하여 압력 1000MPa, 온도 70℃에서 30분간 처리하여 산삼을 추출하는 단계; 상기 추출한 산삼 추출물을 나노리포좀으로 안정화시키는 단계를 포함하는 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 제조방법을 제공한다.In order to achieve the above object, the present invention comprises the steps of extracting wild ginseng by treatment for 30 minutes at pressure 1000MPa, temperature 70 ℃ using an ultra-high pressure treatment machine; It provides a method for producing a cosmetic composition containing the wild ginseng extract stabilized with nano-liposomes comprising the step of stabilizing the extracted wild ginseng extract with nano-liposomes.
이하, 본 발명의 과제 해결수단에 대해 상세히 설명하고자 한다.Hereinafter, the problem solving means of the present invention will be described in detail.
본 발명은 산삼을 압력 1000MPa, 온도 70℃에서 30분간 처리한 후, 추출한 산삼 추출물에 나노리포좀을 혼합하여 안정화된 산삼 추출물을 함유하는 화장료 조성물의 제조방법을 제공한다. The present invention provides a method for preparing a cosmetic composition containing a stabilized wild ginseng extract by treating the wild ginseng at pressure 1000MPa, temperature 70 ° C. for 30 minutes, and then mixing nanoliposomes with the extracted wild ginseng extract.
삭제delete
한편, 본 발명에 사용되는 산삼은 바람직하게는 증기 또는 60∼90℃의 물로 5∼60분간 전처리 과정을 하는 것이 좋다.Meanwhile, the wild ginseng used in the present invention is preferably subjected to a pretreatment process for 5 to 60 minutes with steam or water at 60 to 90 ° C.
한편, 본 발명에서 산삼 추출은, 특정 pH에 한정하는 것은 아니나, 바람직하게는 초고압처리시 초고압기 내부 물의 pH를 1∼6으로 낮춰 처리하는 것이 좋다.On the other hand, in the present invention, the extraction of wild ginseng is not limited to a specific pH, but it is preferable that the pH of the water inside the ultra-high pressure during the ultra-high pressure treatment is reduced to 1-6.
한편, 본 발명에 사용되는 추출용매는 특정의 종류에 한정하는 것은 아니나, 바람직하게는 정제수, 메탄올, 에탄올, 글리세린, 에틸아세테이트, 부틸렌글리콜, 프로필렌글리콜, 디클로로메탄,헥산 및 그의 혼합물로부터 선택된 것이 좋다.On the other hand, the extraction solvent used in the present invention is not limited to a specific kind, but preferably selected from purified water, methanol, ethanol, glycerin, ethyl acetate, butylene glycol, propylene glycol, dichloromethane, hexane and mixtures thereof good.
한편, 본 발명에 사용된 산삼 추출물은 추출액을 일부 또는 전부 농축하여 얻은 농축물, 또는 다시 그 농축물을 건조시켜 제조한 추출 엑기스 및 추출액 중에 함유되고 있는 주효과를 발휘하는 화학물질 그 자체를 포함한다.Meanwhile, the wild ginseng extract used in the present invention includes a concentrate obtained by partially or fully concentrating the extract, or an extract extracted by drying the extract and a chemical substance having a main effect contained in the extract. do.
나노리포좀은 통상적인 리포좀의 형태를 갖는 것으로, 인지질 분자의 양극성 성질을 가지고 있으며, 소수성 부분은 탄화수소 사슬과의 회합을 촉진하고, 극성 머리기는 친수성 성분과의 회합을 촉진하기 때문에 공존하면 불안정한 소수성과 친수성 성분들을 안정화시키는 역할을 한다. 나노리포좀의 평균 입자 지름이 1-100nm이며,, 피부침투의 개선 및 제형 안정성을 개선한다. Nanoliposomes are in the form of conventional liposomes, which have the bipolar nature of phospholipid molecules, hydrophobic moieties promote association with hydrocarbon chains, and polar hair groups promote association with hydrophilic components. It serves to stabilize the hydrophilic components. The average particle diameter of the nanoliposomes is 1-100 nm, which improves skin penetration and improves formulation stability.
한편, 산삼 추출물은 특정의 범위에 한정하는 것은 아니나, 바람직하게는 나노리포좀의 총중량에 대해 0.01~60중량% 함유되는 것이 좋은데, 0.01중량% 미만으로 첨가하는 경우에는, 효과를 기대하기 힘들고, 60중량%를 초과하여 첨가되는 경우에는 뚜렷한 효능 효과의 상승이 보이지 않는다.On the other hand, wild ginseng extract is not limited to a specific range, but preferably contains 0.01 to 60% by weight relative to the total weight of the nanoliposomes, but when added to less than 0.01% by weight, the effect is difficult to expect, 60 When added in excess of% by weight, no marked increase in efficacy effect is seen.
한편, 나노리포좀으로 안정화된 산삼 추출물의 첨가량은 특정의 범위에 한정되는 것은 아니나, 바람직하게는 화장료 조성물의 총 중량에 대해 0.1~30중량% 함유되는 것이 좋은데, 0.1중량% 미만으로 첨가되는 경우에는 유효한 효과를 기대하기 힘들고, 30중량%를 초과하는 경우에는 뚜렷한 효능의 상승이 나타나지 않는다. 또한, 본 발명에 따른 화장료 조성물은 상기의 추출물 외에 본 발명이 목적으로 하는 주 효과를 손상시키지 않는 범위 내에서 바람직하게는 주효과에 상승효과를 줄 수 있는 다른 성분 등을 함유하는 것도 무방하다.On the other hand, the addition amount of the wild ginseng extract stabilized with nanoliposomes is not limited to a specific range, but preferably contains 0.1 to 30% by weight relative to the total weight of the cosmetic composition, if less than 0.1% by weight It is hard to expect an effective effect, and when it exceeds 30% by weight, no marked increase in efficacy is seen. In addition, the cosmetic composition according to the present invention may contain, in addition to the above-mentioned extract, other components which may preferably give a synergistic effect to the main effect within the range of not impairing the main effect of the present invention.
한편, 나노리포좀은 특정의 과정을 통해 수득되는 것에 한정되는 것은 아니나, 바람직하게는 인지질, 글루타치온, 95% 변성 에탄올, 글리세린, 폴리솔베이트 20을 포함하는 리포좀을 고압 유화장치에 통과시켜 수득된 것이 좋다.On the other hand, nanoliposomes are not limited to those obtained through a specific process, but preferably those obtained by passing a liposome comprising phospholipid, glutathione, 95% modified ethanol, glycerin, polysorbate 20 through a high pressure emulsifier good.
한편, 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물은 일예로 피부 미백용, 피부 주름개선용, 피부탄력 강화용으로 사용될 수 있다. Meanwhile, the cosmetic composition containing the wild ginseng extract stabilized with the nanoliposomes of the present invention may be used as an example for skin whitening, skin wrinkle improvement, and skin elasticity.
한편, 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 제형은 특정의 종류에 한정되는 것은 아니나, 일예로 화장수, 젤, 수용성 리퀴드, 크림, 에센스, 수중유(O/W)형 및 유중수(W/O)형으로 이루어진 기초화장료 제형과 수중유형 및 유중수형 메이크업베이스, 파운데이션, 스킨커버, 립스틱, 립그로스, 페이스파우더, 투웨이케익, 아이새도, 치크칼라 및 아이브로우 펜슬류로 이루어진 색조화장료 제형 중에서 선택되는 어느 하나의 외관을 가질 수 있다. On the other hand, the formulation of the cosmetic composition containing the wild ginseng extract stabilized with nanoliposomes of the present invention is not limited to a specific kind, for example, lotion, gel, water-soluble liquid, cream, essence, oil-in-water (O / W) type And cosmetics consisting of water-in-oil (W / O) type, oil-in-water and water-in-oil makeup base, foundation, skin cover, lipstick, lip gloss, face powder, two-way cake, eye shadow, cheek color and eyebrow pencil It may have any one appearance selected from the color cosmetic formulation consisting of.
또한, 이는 선택적으로 에어로졸 형태로 피부에 적용될 수도 있고, 고체 형태 예컨대, 스틱의 형태일 수도 있다. 이는 피부용 케어 제품 및/또는 메이크업 제품으로서 사용될 수도 있다.It may also be applied to the skin, optionally in the form of an aerosol, or may be in the form of a solid such as a stick. It may be used as a skin care product and / or makeup product.
본 발명에 따른 조성물은 또한 화장 분야에서 통상적인 보조제 예컨대 친수성 또는 친유성 겔화제, 친수성 또는 친유성 활성제, 보존제, 항산화제, 용매, 방 향제, 충전제, 차단제, 안료, 흡취제 및 염료를 함유할 수 있다. 이들 다양한 보조제의 양은 당해 분야에서 통상적으로 사용되는 양이며, 예컨대 조성물 총중량에 대해 0.01 내지 20중량%이다. 어떠한 경우라도 보조제 및 그 비율은 본 발명에 따른 화장료 조성물의 바람직한 성질에 악영향을 미치지 않도록 선택될 것이다.The compositions according to the invention may also contain conventional auxiliaries such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, blockers, pigments, odorants and dyes in the cosmetic field. Can be. The amounts of these various adjuvants are amounts conventionally used in the art, such as from 0.01 to 20% by weight relative to the total weight of the composition. In any case, the adjuvant and its proportions will be chosen so as not to adversely affect the desirable properties of the cosmetic composition according to the invention.
상기에서 살펴본 바와 같이 산삼 추출물에 나노리포좀을 혼합하여 안정화된 산삼 추출물을 함유하는 본 발명의 화장료 조성물은 기미, 주근깨 및 피부 색소 침착의 원인이 되는 물질인 멜라닌 생성을 막아주는 티로시나제 활성 억제효과, 멜라닌 합성 억제효과 등의 미백효과와 자유라디칼 소거 효과, 콜라게나제(MMP-1)의 활성 및 발현억제 등의 주름개선효과가 우수하고, 온도 변화에 대해 변색과 분리 및 침전이 발생하지 않는 우수한 안정성을 갖는다. As described above, the cosmetic composition of the present invention containing a wild ginseng extract stabilized by mixing nanoliposomes with a wild ginseng extract has an inhibitory effect on tyrosinase activity, which inhibits melanin production, a substance causing blemishes, freckles and skin pigmentation, and melanin. Excellent whitening effect such as synthetic inhibitory effect, free radical scavenging effect, wrinkle improvement effect such as activity and expression inhibition of collagenase (MMP-1), and excellent stability without discoloration, separation and precipitation in response to temperature change Has
이하, 본 발명의 구성 및 작용에 대해 하기 실시예에서 더욱 상세히 설명하지만, 본 발명의 권리범위가 하기 실시예에만 한정되는 것은 아니고, 이와 등가의 기술적 사상의 변형까지를 포함한다.Hereinafter, the configuration and operation of the present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited to the following examples, and includes modifications of equivalent technical spirit.
<실시예 1> 산삼 추출물의 제조 Example 1 Preparation of Wild Ginseng Extract
산삼을 시료로 선별하여 세척한 후, 초고압처리기를 이용하여 압력 1000MPa하에서 온도를 70℃로 승온시키고 30분간 처리한 후 실온으로 냉각시킨 후 건조기에서 12∼13%의 수분 함량으로 건조하여 산삼을 수득한 후, 수득된 산삼을 정제수로 분산 및 용해하여 산삼 추출물을 제조한 다음, 여과하여 추출액을 수득하였다. (실시예 1).After picking and washing wild ginseng as a sample, using a ultra high pressure processor, the temperature was raised to 70 ° C. under a pressure of 1000 MPa, treated for 30 minutes, cooled to room temperature, and dried in a dryer to a moisture content of 12 to 13% to obtain wild ginseng. After that, the obtained wild ginseng was dispersed and dissolved in purified water to prepare a wild ginseng extract, and then filtered to obtain an extract. (Example 1).
<< 실험예Experimental Example 1> 산삼의 유효성분 함량 측정 1> Determination of active ingredient content of wild ginseng
대조구는 실시예 1과 동일한 동일한 산삼을 시료로 선별하여 세척하여 스팀을 이용하여 3시간 동안 70℃로 승온시킨 후 스팀을 정지하고 실온으로 냉각한 후 약 12∼13%의 수분 함량으로 건조하여 제조하였고, 비교예 1은 4년근 수삼으로 하였다. The control was prepared by screening and washing the same wild ginseng as Example 1, raising the temperature to 70 ° C. for 3 hours using steam, stopping the steam, cooling to room temperature, and drying it to a moisture content of about 12 to 13%. In Comparative Example 1, four-year-old ginseng was used.
각 시료의 총사포닌 함량과 각각의 진세노사이드 함량을 분석하였으며 그 결과를 아래의 표 1에 나타내었다.The total saponin content and ginsenoside content of each sample were analyzed and the results are shown in Table 1 below.
(Ginsenoside)
Ginsenoside
(Ginsenoside)
산삼의 유효성분 함량 측정을 한 결과,실시예 1의 조사포닌 및 진세노사이드의 함량이 높은 것을 확인할 수 있었다.As a result of measuring the active ingredient content of wild ginseng, it was confirmed that the content of the irradiated ponin and ginsenoside of Example 1 is high.
상기의 결과로부터 본 발명의 추출 조건에서 추출된 산삼 추출물은 조사포닌 및 진세노사이드의 함량이 증대된 것을 확인할 수 있었다. From the above results, it was confirmed that the wild ginseng extract extracted under the extraction conditions of the present invention had an increased content of irradiated saponin and ginsenosides.
<실시예 2> 산삼추출물을 안정화시킨 나노리포좀의 제조<Example 2> Preparation of nanoliposomes stabilized wild ginseng extract
삭제delete
나노리포좀은 인지질, 글루타치온, 95% 변성 에탄올, 글리세린, 폴리솔베이트 20(A 상)를 고압 유화시켜 폐쇄된 이중층 구조의 나노 리포좀을 제조하였다. The nanoliposomes were emulsified under high pressure with phospholipid, glutathione, 95% modified ethanol, glycerin, polysorbate 20 (phase A) to prepare a closed bilayer nano liposome.
더욱 상세하게는 표 2의 A상을 95℃까지 가온하여 균일하게 혼합, 용해시킨후, 이를 40℃까지 냉각한 다음, B상을 넣고 혼합하였다. 이를 1200바, 유속 500m/s의 조건하에서 고압 유화장치 (Microfluidizer M210EH, 미국)에 5회 통과시켜, 안정화한 나노리포좀을 얻었다.More specifically, the phase A of Table 2 was heated to 95 ° C., uniformly mixed and dissolved, and then cooled to 40 ° C., followed by mixing with phase B. This was passed through a high pressure emulsifier (Microfluidizer M210EH, USA) five times under conditions of 1200 bar and a flow rate of 500 m / s to obtain a stabilized nanoliposome.
1회 통과하여 얻은 리포좀의 크기는 약 125㎚이었지만, 5회째의 크기는 약 70㎚로 나타났다.The size of the liposome obtained through one pass was about 125 nm, but the size of the fifth pass was about 70 nm.
<< 실험예Experimental Example 2> 미백효과의 측정 2> Measurement of the whitening effect
실시예 2에서 수득한 나노리포좀으로 안정화된 산삼 추출물의 미백효과를 확인하기 위해 티로시나제 (tyrosinase)라는 효소의 억제되는 정도 측정하였다. In order to confirm the whitening effect of the wild ginseng extract stabilized with the nanoliposomes obtained in Example 2, the degree of inhibition of an enzyme called tyrosinase was measured.
티로시나제는 생체내에서 티로신(tyrosine)이라는 물질의 산화과정을 촉진하여 멜라닌이 생성되게 도와주는 효소이다. 본 실험예 2에서는 이 효소의 기능을 억제하여 티로신이 산화되어 멜라닌이라는 흑색의 고분자를 형성하는 것을 억제하는 정도를 측정하는 방법(SH Pomerantz, J Biol chem, 241: 161-168, 1966)을 응용해 미백효과를 판정하였다.Tyrosinase is an enzyme that accelerates the oxidation of tyrosine in vivo and helps melanin production. In Experimental Example 2, a method of inhibiting the function of this enzyme to inhibit the oxidation of tyrosine to form a black polymer called melanin (SH Pomerantz, J Biol chem, 241: 161-168, 1966) was applied. The whitening effect was determined.
코지산, 알부틴, 상백피 추출물 및 실시예 2에서 제조한 산삼 추출물을 시료로 사용하여 티로시나제 활성 억제효과를 조사하였다. 각 시료들의 티로시나제에 대한 저해활성은 시료 15㎕를 96공 평판 배양기(96-well plate)에 넣고, 50mM 인산 완충액(pH 6.5) 150㎕, 1.5mM L-티로신 용액 25㎕를 넣은 후, 머쉬룸 티로시나제(1,500units/㎖, Sigma) 10㎕를 첨가하여 37℃에서 20분간 반응시킨 후, 흡광 광도계 (microplate reader, ELx800, 미국)를 사용하여 490nm에서 흡광도를 측정하여 티로시나제에 대한 활성 저해율을 측정하였다.The inhibitory effect of tyrosinase activity was investigated using kojic acid, arbutin, lettuce extract and wild ginseng extract prepared in Example 2 as samples. The inhibitory activity against tyrosinase of each sample was determined by placing 15 μl of the sample into a 96-well plate incubator, 150 μl of 50 mM phosphate buffer (pH 6.5) and 25 μl of 1.5 mM L-tyrosine solution, followed by mushroom tyrosinase. 10 μl (1,500 units / ml, Sigma) was added and reacted at 37 ° C. for 20 minutes, and then the absorbance was measured at 490 nm using an absorbance photometer (microplate reader, ELx800, USA) to determine the activity inhibition rate against tyrosinase.
IC50 값은 티로시나제 효소 활성을 50% 저해하는 물질의 농도이다.IC 50 The value is the concentration of the substance that inhibits tyrosinase enzyme activity by 50%.
티로시나제 활성 억제효과를 시험한 결과, 산삼 추출물의 IC50 값은 0.01%로 나타났는데, 이는 티로시나제 저해효과가 뛰어나다고 알려진 기존의 미백제인 코지산, 알부틴, 상백피 추출물보다 높게 나타났다. IC 50 of wild ginseng extract was tested for inhibitory effect of tyrosinase activity The value was 0.01%, which was higher than that of kojic acid, arbutin and lettuce extract, which were known to be excellent in tyrosinase inhibitory effect.
상기의 결과로부터 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 우수한 미백효과를 추론할 수 있었다.From the above results, the excellent whitening effect of the cosmetic composition containing the wild ginseng extract stabilized with the nanoliposomes of the present invention could be inferred.
<< 실험예Experimental Example 3> B16F1 3> B16F1 멜라노싸이트를Melanosite 이용한 세포 내 Intracellular Use 티로시나제Tyrosinase 효소 활성 억제효과 측정 Determination of enzyme activity inhibitory effect
실시예 2에서 수득한 나노리포좀으로 안정화된 산삼 추출물의 미백효과를 확인하기 위해 B16F1 멜라노싸이트 내 티로시나제 효소 활성 억제정도를 세포 내 티로시나제 효소 활성을 측정하여 판단한 것이다.In order to confirm the whitening effect of the wild ginseng extract stabilized with the nanoliposomes obtained in Example 2, the degree of inhibition of tyrosinase enzyme activity in B16F1 melanocytes was determined by measuring intracellular tyrosinase enzyme activity.
본 실험예 3에서 사용된 B16F1 멜라노싸이트는 마우스에서 유래한 세포균주이며 티로시나제라는 효소를 합성하는 세포이다. 이 세포의 인공배양 중에 시료를 처리하고 세포에서 티로시나제를 분리하여 효소의 활성을 측정함으로써 티로시나제 효소활성 억제 정도를 비교평가 하였다. 본 실시예에 사용된 B16F1 멜라노싸이트는 ATCC(American Type Culture Collection, 기탁번호 : 6323)로부터 분양받아 사용하였다. B16F1 멜라노싸이트의 티로시나제 효소 활성 억제효과 측정은 다음과 같이 행하였다.B16F1 melanocytes used in Experimental Example 3 are cell strains derived from mice and are cells that synthesize an enzyme called tyrosinase. The degree of inhibition of tyrosinase enzyme activity was evaluated by treating the sample during artificial culture of these cells and by separating the tyrosinase from the cells and measuring the enzyme activity. The B16F1 melanocytes used in this example were used after being sold from ATCC (American Type Culture Collection, Accession No .: 6323). The tyrosinase enzyme activity inhibitory effect of B16F1 melanocytes was measured as follows.
B16F1 멜라노싸이트를 6공 평판배양기에 각 웰 당 2 X 106 농도로 분주하고 세포를 부착시킨 후 독성을 유발하지 않는 농도로 시료를 처리하여 72시간 동안 배양하였다. 72시간 배양 후 세포를 트립신(Trypsin) -EDTA로 떼어낸 후 세포수를 측정한 다음 원심 분리하여 세포를 회수하였다. 세포 펠릿을 PBS로 1회 세척한 후 균질화 버퍼(50mM 소듐 포스페이트, pH 6.8, 1% Triton X-100, 2mM PMSF) 1㎖를 첨가하여 5분간 와류하여 세포를 파쇄하고, 원심분리(3,000rpm, 10분)하여 상등액을 회수하였다. 50mM 소듐 포스페이트 버퍼(pH 6.5)에 1.5mM L-티로신, 0.06mM L-도파, 세포 상등액을 각각 넣고, 37℃에서 30분간 배양한 후 흡광 광도계로 490㎚에서 흡광도를 측정하여 티로시나제 효소 활성 억제효과를 측정하였다. B16F1 melanocytes were dispensed at a concentration of 2 X 10 6 per well in a 6-hole plate incubator, and the cells were attached and incubated for 72 hours by treating the sample at a concentration that does not cause toxicity. After 72 hours of incubation, the cells were detached with trypsin-EDTA, and then the number of cells was measured and centrifuged to recover the cells. Wash the cell pellet once with PBS, add 1 ml of homogenization buffer (50 mM sodium phosphate, pH 6.8, 1% Triton X-100, 2 mM PMSF), vortex for 5 minutes, disrupt the cells, and centrifuge (3,000 rpm, 10 minutes) to recover the supernatant. Put 1.5mM L-tyrosine, 0.06mM L-dopa, and cell supernatant into 50mM sodium phosphate buffer (pH 6.5), and incubate at 37 ℃ for 30 minutes and measure the absorbance at 490nm with an absorbance photometer to inhibit tyrosinase enzyme activity. Was measured.
IC50 값은 세포내 티로시나제 효소의 활성을 50% 저해하는 물질의 농도이다.IC 50 value is the concentration of a substance that inhibits the activity of intracellular tyrosinase enzyme by 50%.
B16F1 멜라노싸이트의 티로시나제 효소 활성 억제효과를 측정한 결과, 산삼 추출물의 IC50 값은 0.02%로 나타났는데, 기존의 미백제인 코지산, 알부틴, 유용성 감초 추출물, 상백피 추출물 보다 낮은 농도에서도 티로시나제의 활성을 효과적으로 저해하는 것으로 측정되었다. As a result of measuring the inhibitory effect of tyrosinase enzyme activity of B16F1 melanocytes, IC 50 value of wild ginseng extract was 0.02%, and the activity of tyrosinase was lowered at lower concentrations than koji acid, arbutin, oil-soluble licorice extract, and lettuce extract. It was determined to inhibit effectively.
이와 같은 결과로 볼 때, 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 우수한 미백효과를 추론할 수 있었다.As a result, it was possible to deduce the excellent whitening effect of the cosmetic composition containing the wild ginseng extract stabilized with the nanoliposomes of the present invention.
<< 실험예Experimental Example 4> B16F1 4> B16F1 멜라노싸이트를Melanosite 이용한 멜라닌 생성 억제효과 측정 Measurement of melanin production inhibitory effect
실시예 2에서 수득한 나노리포좀으로 안정화된 산삼 추출물의 미백효과를 확인하기 위해 B16F1 멜라노싸이트에 대한 멜라닌 생성 억제 정도에 따라 미백효과를 판단하였다.In order to confirm the whitening effect of the wild ginseng extract stabilized with the nanoliposomes obtained in Example 2, the whitening effect was determined according to the degree of inhibition of melanin production for B16F1 melanocytes.
본 실험예 4예에 사용된 B16F1 멜라노싸이트는 마우스에서 유래한 세포균주이며, 멜라닌이라는 흑색색소를 분비하는 세포이다. 이 세포의 인공배양 중에 시료를 처리하여 멜라닌 흑색색소가 감소하는 정도를 비교 평가하였다. 본 실시예에 사용된 B16F1 멜라노싸이트는 ATCC(American Type Culture Collection, 기탁번호 : 6323)로부터 분양 받아 사용하였다.The B16F1 melanocytes used in the four examples of this experiment are cell strains derived from mice, and cells that secrete a black pigment called melanin. Samples were treated during the artificial culture of these cells to evaluate the degree of melanin black pigment reduction. The B16F1 melanosite used in this example was used after being sold from ATCC (American Type Culture Collection, Accession No .: 6323).
B16F1 멜라노싸이트의 멜라닌 생합성 억제효과 측정은 다음과 같이 행하였다. B16F1 멜라노싸이트를 6공 평판배양기에 각 웰당 2 X 106농도로 분주하고 세포를 부착시킨 후 독성을 유발하지 않는 농도로 시료를 처리하여 72시간 동안 배양하였다. 72시간 배양 후 세포를 트립신-EDTA로 떼어낸 후 세포수를 측정한 다음 원심분리하여 세포를 회수하였다. 세포 내 멜라닌의 정량은 로탄(R. Lotan and D. Lotan, Cancer Res, 40: 3345-3350, 1980)의 방법을 변형하여 실시하였다. 세포 펠릿을 PBS로 1회 세척한 후 균질화 버퍼액(50mM 소듐 포스페이트, pH 6.8, 1% Triton X-100, 2mM PMSF) 1㎖를 첨가하여 5분간 와류하여 세포를 파쇄하였다. 원심분리(3,000rpm, 10분)하여 얻은 세포 여액에 1N NaOH(10% DMSO)를 첨가하여 추출된 멜라닌을 용해한 후 흡광광도계로 405㎚에서 멜라닌의 흡광도를 측정한 다음, 멜라닌을 정량하여 시료의 멜라닌 생성 저해율(%)을 측정하였다. The melanin biosynthesis inhibitory effect of B16F1 melanocytes was measured as follows. B16F1 melanocytes were dispensed at a concentration of 2 X 10 6 per well in a 6-hole plate incubator, and the cells were attached and incubated for 72 hours by treating the sample at a concentration that does not cause toxicity. After 72 hours of incubation, the cells were detached with trypsin-EDTA, and the cells were counted and centrifuged to recover the cells. Quantification of intracellular melanin was performed by modifying the method of Rotan (R. Lotan and D. Lotan, Cancer Res, 40: 3345-3350, 1980). The cell pellet was washed once with PBS, and then 1 ml of homogenization buffer solution (50 mM sodium phosphate, pH 6.8, 1% Triton X-100, 2 mM PMSF) was added to vortex for 5 minutes to disrupt the cells. Melt the extracted melanin by adding 1N NaOH (10% DMSO) to the cell filtrate obtained by centrifugation (3,000 rpm, 10 minutes), and measure the absorbance of melanin at 405 nm with an absorbance spectrometer. Melanin production inhibition rate (%) was measured.
IC50 값은 멜라닌 생성을 50% 저해하는 물질의 농도이다.IC 50 The value is the concentration of the substance that inhibits melanin production by 50%.
B16F1 멜라노싸이트의 멜라닌 생성 억제효과를 시험한 결과, 산삼 추출물의 IC 50 값은 0.004%로 측정되었는데, 기존의 미백제인 하이드로퀴논, 알부틴, 유용성 감초 추출물, 상백피 추출물 보다 우수한 멜라닌 합성 저해 효과를 나타냈다.As a result of testing the melanin production inhibitory effect of B16F1 melanocytes, the IC 50 value of the wild ginseng extract was measured to be 0.004%, showing melanin synthesis inhibitory effect better than the existing whitening agents hydroquinone, arbutin, oil-soluble licorice extract, and lettuce extract.
상기의 결과로부터 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 우수한 미백효과를 추론할 수 있었다.From the above results, the excellent whitening effect of the cosmetic composition containing the wild ginseng extract stabilized with the nanoliposomes of the present invention could be inferred.
<< 실험예Experimental Example 5> 항산화 효과 측정 5> Antioxidant effect measurement
실시예 2에서 수득한 나노리포좀으로 안정화된 산삼 추출물의 항산화효과를 확인하기 위해 활성산소 라디칼 소거효과를 측정하였다.The active oxygen radical scavenging effect was measured to confirm the antioxidant effect of the wild ginseng extract stabilized with the nanoliposomes obtained in Example 2.
활성산소 라디칼 소거작용은 Furuno 등(K Furuno, et al., Biol Pharm Bull, 25(1): 19-23, 2002)의 방법에 따라 각 시료의 크산틴- 크산틴옥시다제 시스템에 의해 생성된 활성산소를 소거하는 효과를 측정하였다. 0.05M Na2CO3 완충액에 3mM 크산틴, 3mM EDTA, 0.72mM 니트로블루 테트라졸리움(nitroblue tetrazolium; NBT), 0.15% BSA(bovine serum albumin) 용액과 시료를 각각 첨가하여 혼합한 다음, 25℃에서 10분간 반응하였다. 그 후 각 시험관에 크산틴옥시다제(0.25U/㎖)용액을 첨가하여 25℃에서 30분간 반응한 후, 565㎚에서 흡광도를 측정하였다.The reactive oxygen radical scavenging activity was generated by the xanthine-xanthine oxidase system of each sample according to the method of Furuno et al., Biol Pharm Bull, 25 (1): 19-23, 2002). The effect of scavenging free radicals was measured. 3 mM xanthine, 3 mM EDTA, 0.72 mM nitroblue tetrazolium (NBT), 0.15% BSA (bovine serum albumin) solution and sample were added to 0.05 M Na 2 CO 3 buffer and mixed at 25 ° C. The reaction was carried out for 10 minutes. Then, xanthine oxidase (0.25 U / ml) solution was added to each test tube, and it reacted at 25 degreeC for 30 minutes, and the absorbance was measured at 565 nm.
항산화 효과 측정한 결과, 실시예 2는 대표적인 항산화제인 녹차 추출물과 비타민 E와 농도 대비 항산화 효과(%)를 비교하였을 때, 우수한 항산화 효과를 나타냄을 알 수 있었다.As a result of measuring the antioxidant effect, Example 2 shows that the antioxidant effect (%) compared to the concentration of green tea extract and vitamin E, a representative antioxidant, showed an excellent antioxidant effect.
상기의 결과로부터 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 우수한 항산화 효과를 추론할 수 있었다.From the above results, it was possible to deduce the excellent antioxidant effect of the cosmetic composition containing wild ginseng extract stabilized with the nanoliposomes of the present invention.
<< 실험예Experimental Example 6> 콜라겐 합성 효과 측정 6> Collagen synthesis effect measurement
실시예 2에서 수득한 나노리포좀으로 안정화된 산삼 추출물의 콜라겐 합성효과를 관찰하기 위해 인간으로부터 직접 채취하거나 상업적으로 구입한 인간의 섬유아세포에 처리하여 실험하였다. 대조군은 실시예를 처리하지 않은 세포 배양액의 반응 흡광도로 하였다.In order to observe the collagen synthesis effect of the wild ginseng extract stabilized with the nanoliposomes obtained in Example 2, experiments were performed directly on human fibroblasts obtained from humans or purchased commercially. The control group was taken as the reaction absorbance of the cell culture without the Example.
96공 평판 배양기에 2.5% 우 태아 혈청이 함유된 DMEM(Dulbecco's Modified Eagle's Media)과 인간 섬유아세포 (5 X 103세포/웰)를 넣고, 70~80% 정도 자랄 때까지 배양하였다. 그 다음 산삼 추출물을 각각 0.01% 및 0.001%의 농도로 1일 처리 후 세포배양액을 채취하여 콜라겐 단백질 측정기구(Catalog No. : MK 101, Takara Shuzo Co. Ltd, 일본)를 이용하여 콜라겐 합성량을 측정하였다. 측정방법은 우선 1차 콜라겐 항체가 균일하게 도포된 96공 평판 배양기에 채취된 세포 배양액을 넣고 3시간동안 항원-항체 반응을 실시하였다. 3시간 후 발색단이 결합된 2차 콜라겐 항체를 96공 평판 배양기에 넣고 15분간 반응시켰다. 15분 후 발색 유발물질을 넣어 실온에서 발색시키고, 1M 황산을 넣어 발색을 중지시켰다. 반응색의 색깔은 노란색을 띠며, 반응의 정도에 따라 진한 정도가 달라진다.DMEM (Dulbecco's Modified Eagle's Media) containing 2.5% fetal bovine serum and human fibroblasts (5 X 10 3 cells / well) were put into a 96-hole plate incubator and cultured until 70-80% growth. Next, the ginseng extract was treated with 0.01% and 0.001%, respectively, and the cell culture solution was collected for 1 day. The collagen synthesis amount was measured using a collagen protein measuring instrument (Catalog No .: MK 101, Takara Shuzo Co. Ltd, Japan) Measured. In the measurement method, first, the cell culture solution collected in a 96-hole plate incubator uniformly coated with primary collagen antibody was subjected to antigen-antibody reaction for 3 hours. After 3 hours, the chromophore-bound secondary collagen antibody was placed in a 96-hole plate incubator and allowed to react for 15 minutes. After 15 minutes, the color developing agent was added to develop color at room temperature, and 1M sulfuric acid was added to stop the color development. The color of the reaction color is yellow, and the intensity of the reaction varies depending on the degree of reaction.
노란색을 띤 96공 평판 배양기를 흡광광도계를 이용하여 450㎚에서 측정하였다. A yellowish 96-hole plate incubator was measured at 450 nm using an absorbance spectrometer.
콜라겐 합성 효과 측정한 결과, 실시예 2는 우수한 콜라겐 생성 촉진효과를 나타냈다.As a result of measuring the collagen synthesis effect, Example 2 showed the excellent collagen production | stimulation effect.
상기의 결과로부터 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 우수한 콜라겐 생성 촉진 효과를 추론할 수 있었다.From the above results, it was possible to infer an excellent collagen production promoting effect of the cosmetic composition containing the wild ginseng extract stabilized with the nanoliposomes of the present invention.
<< 실험예Experimental Example 7> 7> MMPMMP -1의 활성 억제효과 측정-1 activity inhibition effect
실시예 2에서 제조된 나노리포좀으로 안정화된 산삼 추출물의 기질 금속단백질 분해효소(MMP-1) 활성 억제효과 측정은 Wang 등(Y. Wang, et al., J Biol. Chem., 274: 33043-33049, 1999)이 사용한 방법을 약간 변형하여 실시하였다. 즉, 반응 완충액 100㎕에 0.25㎎/㎖로 반응 완충액에 용해한 DQ-콜라겐 20㎕와 시료 40㎕를 첨가하고 0.5 unit로 희석된 콜라게나제 40㎕를 첨가하였다. 암소, 실온에서 20분 경과 후 형광 분광광도계(LS55, PERKIN ELMER, 미국)를 이용하여 흡수파장 495㎚, 방출파장 515㎚로 형광값을 측정하였고, 대조그룹으로서 효소액 대신 반응 완충액을 효소와 동량 첨가하여 형광값을 측정하였다. 시료 자체의 형광값도 측정하여 효소활성 계산시 보정하였다. 양성 대조군으로 MMP-1 활성 저해 작용이 있는 것으로 알려진 1,10-페난트롤린(phenanthroline)을 사용하였다.The inhibitory effect of the substrate metalloproteinase (MMP-1) activity of the wild ginseng extract stabilized with the nanoliposome prepared in Example 2 was measured by Wang et al. (Y. Wang, et al., J Biol. Chem., 274: 33043-). 33049, 1999). That is, 20 µl of DQ-collagen and 40 µl of sample dissolved in the reaction buffer at 0.25 mg / ml were added to 100 µl of reaction buffer, and 40 µl of collagenase diluted to 0.5 unit was added. After 20 minutes at room temperature, the fluorescence value was measured using a fluorescence spectrophotometer (LS55, PERKIN ELMER, USA) at an absorption wavelength of 495 nm and an emission wavelength of 515 nm. The fluorescence value was measured. The fluorescence value of the sample itself was also measured and corrected in enzymatic activity calculation. As a positive control, 1,10-phenanthroline (phenanthroline), which is known to have an inhibitory effect on MMP-1 activity, was used.
MMP-1의 활성 억제효과 측정한 결과, 실시예 2는 농도 의존적으로 콜라게나제 활성을 저해하는 것으로 나타났다. 양성 대조군으로 사용된 1,10-페난트롤린의 경우는 2mM에서 73% 활성 저해효과를 나타내었다.As a result of measuring the inhibitory effect of MMP-1, Example 2 was found to inhibit collagenase activity in a concentration-dependent manner. The 1,10-phenanthroline used as a positive control showed 73% activity inhibition at 2 mM.
이와 같은 결과로 볼 때 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 우수한 콜라게나제 활성 저해효과를 추론할 수 있었다.As a result, it was possible to deduce the excellent collagenase activity inhibitory effect of the cosmetic composition containing wild ginseng extract stabilized with the nanoliposomes of the present invention.
<< 실험예Experimental Example 8> 자외선 조사 후 8> After UV irradiation MMPMMP -1 발현억제 측정-1 expression inhibition measurement
실시예 2에서 수득한 나노리포좀으로 안정화된 산삼 추출물의 UV 조사 및 시료 첨가 후 MMP-1의 발현량을 측정하기 위해서 ELISA(Enzyme Linked ImmunoSorbent Assay)를 실시하였다(S. E. Dunsmore, et al., J Biol. Chem., 271: 24576-24582, 1996).Enzyme Linked ImmunoSorbent Assay (ELISA) was performed to measure the expression level of MMP-1 after UV irradiation and sample addition of wild ginseng extract stabilized with nanoliposomes obtained in Example 2 (SE Dunsmore, et al., J Biol Chem., 271: 24576-24582, 1996).
UV 챔버를 이용하여 인간 섬유아세포에 UVA를 6.3J/㎠의 에너지로 조사하였다. 자외선 조사량과 배양시간은 예비 실험을 통하여 섬유아세포에서 MMP 발현량이 최대가 되는 조건을 확립하였다. 음성 대조군은 은박지로 싸서 UVA의 환경에 같은 시간 유지하였다. UVA 방출량은 UV 라디오미터를 이용하여 측정하였다. UVA가 조사되는 동안의 세포는 이전에 분주된 배지 그대로이고 UVA를 조사한 후 샘플이 들어간 배지로 교환하여 24시간 배양 후 배지를 회수하여 96공 평판 배양기에 코팅하였다. 일차항체(단일클론항체)를 처리하고 37℃에서 90분간 반응시켰다. 이차항체인 항마우스 이뮤노글로불린 지(alkaline phosphatase conjugated anti-mouse IgG)를 다시 90분정도 반응시킨 후, 완충용액으로 세척한 다음 알카린 포스파타제 기질용액(1㎎/㎖p-nitrophenyl phosphate in diethanolamine buffer)을 상온에서 30분간 반응시키고 흡광광도계를 이용하여 405㎚에서 흡광도를 측정하였다.Human fibroblasts were irradiated with UVA at an energy of 6.3 J / cm 2 using a UV chamber. UV irradiation dose and culture time were established through preliminary experiments to maximize the expression of MMP in fibroblasts. Negative controls were wrapped in tinfoil and maintained at the same time in the environment of UVA. UVA emission was measured using a UV radiometer. The cells during the UVA irradiation were intact with the previously dispensed medium, and were irradiated with UVA, exchanged with the medium containing the sample, and then cultured for 24 hours, and the medium was recovered and coated in a 96-hole plate incubator. The primary antibody (monoclonal antibody) was treated and reacted at 37 ° C. for 90 minutes. The secondary antibody, anti-mouse immunoglobulin (alkaline phosphatase conjugated anti-mouse IgG) was reacted for another 90 minutes, washed with a buffer solution, and then washed with an alkaline phosphatase substrate solution (1 mg / ml p-nitrophenyl phosphate in diethanolamine buffer). ) Was reacted at room temperature for 30 minutes and absorbance was measured at 405 nm using an absorbance spectrometer.
이때, 실시예 2를 처리하지 않은 세포배양액의 반응 흡광도를 대조군으로 하였다.At this time, the reaction absorbance of the cell culture solution not treated with Example 2 was used as a control.
자외선 조사 후 MMP-1 발현억제 측정한 결과, 실시예 2는 농도 의존적으로 MMP-1 발현 저해효과를 나타내었다. 양성 대조군으로 사용된 레티노인산의 경우는 3.5uM에서 52% 발현 저해효과를 나타내었다. Inhibition of MMP-1 expression after UV irradiation As a result, Example 2 showed the effect of inhibiting MMP-1 expression in a concentration-dependent manner. Retinoic acid used as a positive control showed a 52% expression inhibition effect at 3.5uM.
상기의 결과로부터 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 우수MMP-1 발현 저해효과를 추론할 수 있었다. From the above results, it could be inferred from the excellent MMP-1 expression inhibitory effect of the cosmetic composition containing wild ginseng extract stabilized with the nanoliposomes of the present invention.
<< 실시예Example 3> 3> 화장료Cosmetics 제조 Produce
상기 실시예 2에서 수득한 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료를 제조하였다.A cosmetic containing a wild ginseng extract stabilized with the nanoliposomes obtained in Example 2 was prepared.
하기 화장료의 성분들은 표 10와 같았고, 통상적인 화장료의 제조방법에 따라 에멀젼을 제조하였다(실시예 3, 실시예 4, 실시예 5, 비교예 2). The components of the following cosmetics were as shown in Table 10, and an emulsion was prepared according to a conventional cosmetic preparation method (Example 3, Example 4, Example 5, and Comparative Example 2).
<< 실험예Experimental Example 9> 미백효과 측정 9> Measure whitening effect
상기에서 제조된 실시예 3과 비교예 2의 미백효과에 대해 측정하였다. The whitening effect of Example 3 and Comparative Example 2 prepared above was measured.
실험자(20세~35세의 여성) 20명을 대상으로 얼굴 오른쪽 부위에는 실시예 3을, 얼굴 왼쪽 부위에는 비교예 2를 각각 1일 2회씩 연속 2개월간 도포하였다. 시험 완료 후 얼굴 좌우 양편의 도포 부위 피부를 화상분석기 및 색차계로 얼굴색을 비교하여 가장 어두운 색을 5, 중간색을 3, 가장 환한 색을 1로 정하고 그 중간 정도를 어림잡아 평가하였다. (n=20, p<0.01)20 experimenters (20-35 year old female) were applied to Example 3 on the right side of the face and Comparative Example 2 on the left side of the face, twice a day for 2 consecutive months. After completion of the test, the skins of the application areas on both sides of the face were compared by using an image analyzer and a color difference meter, and the darkest color was set to 5, the middle color to 3, and the brightest color to 1, and the intermediate level was estimated. (n = 20, p <0.01)
화장료의 미백효과를 측정한 결과, 실시예 3을 도포한 실험자의 안면 피부에서 우수한 미백효과가 나타났다.As a result of measuring the whitening effect of the cosmetics, the whitening effect was excellent in the facial skin of the experimenter applied to Example 3.
상기의 결과로부터 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 우수한 미백효과를 확인할 수 있었다. From the above results, it was confirmed that the excellent whitening effect of the cosmetic composition containing the wild ginseng extract stabilized with the nanoliposomes of the present invention.
<< 실험예Experimental Example 10> 피부 잔주름의 개선효과 측정 10> Measure the improvement effect of skin wrinkles
실시예 4와 비교예 2를 사람을 대상으로 적용하여 피부 잔주름 개선효과를 평가하였다.Example 4 and Comparative Example 2 were applied to humans to evaluate the effect of improving skin wrinkles.
실험자(20세~35세의 여성) 20명을 대상으로 얼굴 오른쪽부위에는 실시예 2를, 얼굴 왼쪽 부위에는 비교예 2를 각각 1일 2회씩 연속 2개월간 도포하였다.Twenty test subjects (20-35 year old female) were applied to Example 2 on the right side of the face and Comparative Example 2 on the left side of the face, twice a day for 2 consecutive months.
실험완료 후 피부 잔주름 개선 효과는 제품 사용 전과 2개월간 사용 후에 안면 눈꼬리 주위의 주름을 실리콘 수지 복사물(레플리카)로 채취하고, 이것을 피부 미세 주름 장치와 피부 영상 분석기로 눈가 잔주름의 상태를 비교하였다.After the experiment was completed, wrinkles around the face of the eyes were collected with a silicone resin copy (replica) before and after using the product for two months, and the skin fine wrinkle device and the skin image analyzer were used to compare the condition of the eye wrinkles.
화장료의 피부 잔주름의 개선효과 측정한 결과, 실시예 4가 비교예 2보다 사용 전 대비 주름 감소율이 높게 나타났다. As a result of measuring the improvement effect of the skin wrinkles of the cosmetics, Example 4 was found to have a higher wrinkle reduction rate compared to Comparative Example 2.
상기의 결과로부터 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 우수한 피부 잔주름 개선 효과를 확인할 수 있었다. From the above results, it was confirmed that the excellent skin wrinkle improvement effect of the cosmetic composition containing the wild ginseng extract stabilized with the nanoliposomes of the present invention.
<< 실험예Experimental Example 11> 안정성 측정 11> Stability Measurement
본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료에 대한 제형의 안정성을 하기의 방법으로 측정하였다.The stability of the formulation for the cosmetic containing the wild ginseng extract stabilized with the nanoliposomes of the present invention was measured by the following method.
실시예 3과 비교예 3(실시예 2의 나노리포좀으로 안정화된 산삼 추출물을 사용하는 대신, 실시예 1의 산삼 추출물 10 중량%(즉, 나노리포좀으로 안정화시키지 않은 산삼 추출물)를 첨가한 것을 제외하고는, 실시예 3과 동일한 방법으로 제조된 에멀젼)을 45℃로 일정하게 유지되는 항온조에서 불투명 초자 용기에 담아 12주 동안 보관한 시료, 4℃로 일정하게 유지되는 완전히 차광된 냉장고 내에서 불투명 초자 용기에 담아 12주 동안 보관한 시료, -5℃에서 45℃를 순환하는 순환 챔버(1회/일)에 12주 동안 보관한 시료에 대하여 분리, 변색 정도 및 침전 정도를 비교 측정하였다. 제품 분리 및 변색 정도를 다음의 6등급으로 분류하여 평가하였다(0: 변화 없음, 1: 극히 조금 분리(변색), 2: 조금 분리(변색), 3: 조금 심하게 분리(변색), 4: 심하게 분리(변색), 5: 극히 심하게 분리(변색)).Example 3 and Comparative Example 3 (instead of using the wild ginseng extract stabilized with the nanoliposomes of Example 2, except that 10% by weight of the wild ginseng extract of Example 1 (ie, the wild ginseng extract not stabilized with the nanoliposomes) was added Then, the emulsion prepared in the same manner as in Example 3) was stored in an opaque glass container in a constant temperature bath at 45 ℃ constant stored for 12 weeks, opaque in a completely shaded refrigerator kept at 4 ℃ constant For samples stored in a vial container for 12 weeks and samples stored for 12 weeks in a circulation chamber (once / day) circulating at -5 ° C to 45 ° C, separation, degree of discoloration and precipitation were measured. The degree of separation and discoloration of the product was classified into six grades (0: no change, 1: very slight separation (discoloration), 2: slight separation (discoloration), 3: slight separation (discoloration), 4: severely Separation (discoloration), 5: Extremely severe separation (discoloration).
화장료 에멀젼의 분리 및 변색 정도를 측정한 결과, 나노리포좀으로 안정화된 실시예 3은 4℃, 45℃ 및 순환 시험에서 변색이나 분리 증상이 없이 안정하였으나, 나노리포좀을 함유하지 않은 비교예 3은 분리(변색)가 일어나 불안정상태를 나타냈다.As a result of measuring the degree of separation and discoloration of the cosmetic emulsion, Example 3 stabilized with nanoliposomes was stable without discoloration or separation symptoms at 4 ° C., 45 ° C. and circulation test, but Comparative Example 3 containing no nano liposome was isolated. Discoloration occurred, indicating instability.
상기의 결과로 부터 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료의 우수한 안정성을 확인할 수 있었다.From the above results it was confirmed that the excellent stability of the cosmetic containing the wild ginseng extract stabilized with the nanoliposomes of the present invention.
또한, 제품 침전 정도를 다음의 6등급으로 분류하여 평가하였다(0: 변화 없음, 1: 극히 조금 침전, 2: 조금 침전, 3: 조금 심하게 침전, 4: 심하게 침전, 5: 극히 심하게 침전).In addition, the degree of product precipitation was evaluated by classifying into the following six grades (0: no change, 1: very little precipitation, 2: little precipitation, 3: little precipitation, 4: severe precipitation, 5: extremely severe precipitation).
화장료 에멀젼의 침전 정도를 측정한 결과, 나노리포좀으로 안정화된 실시예 3은 침전이 발생하지 않았고, 나노리포좀을 함유하지 않은 비교예 3은 침전이 발생하였다. As a result of measuring the degree of precipitation of the cosmetic emulsion, Example 3 stabilized with nanoliposomes did not occur precipitation, Comparative Example 3 did not contain nanoliposomes precipitated.
상기의 결과들로부터 산삼 추출물에 나노리포좀을 첨가하지 않으면 제형 내의 다른 약한 이온성 고분자들과 쉽게 반응하여 침전 및 변색이 발생한다는 사실을 확인할 수 있었고, 본 발명의 나노리포좀으로 안정화된 산삼 추출물을 함유하는 화장료 조성물의 안정성도 확인할 수 있었다. From the above results, it was confirmed that the addition of nanoliposomes to wild ginseng extract easily reacts with other weak ionic polymers in the formulation, causing precipitation and discoloration, and contains the wild ginseng extract stabilized with the nanoliposomes of the present invention. The stability of the cosmetic composition was also confirmed.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080035200A KR100992042B1 (en) | 2008-04-16 | 2008-04-16 | preparation for cosmetic composition containg ginseng extract stabilized by nanoliposome |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080035200A KR100992042B1 (en) | 2008-04-16 | 2008-04-16 | preparation for cosmetic composition containg ginseng extract stabilized by nanoliposome |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090109789A KR20090109789A (en) | 2009-10-21 |
KR100992042B1 true KR100992042B1 (en) | 2010-11-04 |
Family
ID=41537699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080035200A KR100992042B1 (en) | 2008-04-16 | 2008-04-16 | preparation for cosmetic composition containg ginseng extract stabilized by nanoliposome |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100992042B1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101315440B1 (en) * | 2010-10-20 | 2013-10-07 | 주식회사 청담화장품 | Nanoemulsion containing wild ginseng extract and personal care composition comprising the same |
KR101836354B1 (en) * | 2015-03-09 | 2018-03-09 | 주식회사 한국화장품제조 | Cosmetic composition comprising oil of cultured root of wild ginseng |
CN105342867B (en) * | 2015-12-15 | 2020-04-03 | 上海相宜本草化妆品股份有限公司 | A submicron lipid carrier of herbal composition for coating skin surface, and its preparation method |
KR102007736B1 (en) | 2018-01-22 | 2019-08-07 | 주식회사 한국화장품제조 | Niosome composition comprising extracts of cultured korean wild ginseng and personal care composition containing the same |
KR102587666B1 (en) | 2023-05-18 | 2023-10-11 | 주식회사 에이바이오머티리얼즈 | Cosmetic composition comprising stabilized glutathione by lipid nanoparticles and physiologically active materials |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100501399B1 (en) * | 2003-05-23 | 2005-07-18 | 주식회사 코리아나화장품 | Cosmetic Compostion for Preventing Skin Aging Comprising Plant Extract as Oriental Medicine Stabilized in Nanoliposome |
-
2008
- 2008-04-16 KR KR1020080035200A patent/KR100992042B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100501399B1 (en) * | 2003-05-23 | 2005-07-18 | 주식회사 코리아나화장품 | Cosmetic Compostion for Preventing Skin Aging Comprising Plant Extract as Oriental Medicine Stabilized in Nanoliposome |
Also Published As
Publication number | Publication date |
---|---|
KR20090109789A (en) | 2009-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101550917B1 (en) | Composition for applying to skin externally containing extract from seeds of ginseng | |
KR101438367B1 (en) | Composition of skin external application containing ginseng fruit extracts | |
KR101035858B1 (en) | Sargassum sp. extract that have low photo-induced cytotoxicity, preparation method thereof and cosmetic composition containing the same | |
KR20090003144A (en) | Cosmetic composition containing allithiamine | |
KR100732564B1 (en) | Cosmetic composition containing extract of fraxinus chinensis | |
KR100992042B1 (en) | preparation for cosmetic composition containg ginseng extract stabilized by nanoliposome | |
KR100758960B1 (en) | Cosmetic composition containing diospyros kaki fruit extract stabilized with nanoliposome | |
CN105267268B (en) | Method for preparing folium Ginseng extract and cosmetic composition containing the same as effective component | |
KR101026879B1 (en) | Producing method of cosmetic composition for improving skin wrinkle | |
KR101129239B1 (en) | Cosemtics composition containing the extract of allithiamine fermented | |
KR100669362B1 (en) | Manufacturing method for extract of selaginella tamariscina using traditional process and cosmetic composition containing the same | |
KR20100018139A (en) | A skin-care agent containing sedum sarmentosum extracts and lipoic acid-peg conjugated compounds | |
KR100781957B1 (en) | A cosmetic composition containing an extract of typhae pollen | |
KR101427573B1 (en) | Cosmetic composition for improving skin acne containing ginseng fruit extracts | |
KR101146634B1 (en) | Fraction of Citrus unshiu Fruit Peel Extract and Use Thereof | |
KR100542446B1 (en) | A cosmetic composition containing an extract of capsosiphon fulvescens | |
KR20090097550A (en) | Cosmetic composition containing schizandrin and extracts | |
KR100525994B1 (en) | A cosmetic composition containing an extract of herbal medicines | |
KR100732563B1 (en) | Cosmetic composition containing extract of pterocarpus santalinus | |
KR100552269B1 (en) | A cosmetic composition containing extract of Campsis grandiflora and/or Torreya nucifera seed | |
KR20030086933A (en) | A cosmetic composition containing an Extract of Zostera Marina L. | |
KR20100004531A (en) | Cosmetic composition containing hosta plantaginea extract | |
KR100588830B1 (en) | A cosmetic composition for anti-aging containing an extract of melothria heterophylla | |
KR101280306B1 (en) | A cosmetic composition for anti-aging containing an extract of poncirus trifoliata by bioconversion | |
KR100669361B1 (en) | Cosmetic composition containing Siphonostegia chinenesis extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131029 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141029 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20161028 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171024 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191017 Year of fee payment: 10 |